182 related articles for article (PubMed ID: 26138196)
21. New Insights on KCa3.1 Channel Modulation.
Manfroni G; Ragonese F; Monarca L; Astolfi A; Mancinelli L; Iannitti RG; Bastioli F; Barreca ML; Cecchetti V; Fioretti B
Curr Pharm Des; 2020; 26(18):2096-2101. PubMed ID: 32175839
[TBL] [Abstract][Full Text] [Related]
22. KCa3.1 Channels and Glioblastoma: In Vitro Studies.
Klumpp L; Sezgin EC; Skardelly M; Eckert F; Huber SM
Curr Neuropharmacol; 2018; 16(5):627-635. PubMed ID: 28786347
[TBL] [Abstract][Full Text] [Related]
23. KCa3.1-Dependent Hyperpolarization Enhances Intracellular Ca2+ Signaling Induced by fMLF in Differentiated U937 Cells.
Penna A; Stutzin A
PLoS One; 2015; 10(9):e0139243. PubMed ID: 26418693
[TBL] [Abstract][Full Text] [Related]
24. Crocin Improves the Endothelial Function Regulated by Kca3.1 Through ERK and Akt Signaling Pathways.
Yang H; Li X; Liu Y; Li X; Li X; Wu M; Lv X; Chunhua C; Ding X; Zhang Y
Cell Physiol Biochem; 2018; 46(2):765-780. PubMed ID: 29621746
[TBL] [Abstract][Full Text] [Related]
25. Complementary roles of KCa3.1 channels and β1-integrin during alveolar epithelial repair.
Girault A; Chebli J; Privé A; Trinh NT; Maillé E; Grygorczyk R; Brochiero E
Respir Res; 2015 Sep; 16(1):100. PubMed ID: 26335442
[TBL] [Abstract][Full Text] [Related]
26. Activity-Dependent Facilitation of Ca
Sahu G; Asmara H; Zhang FX; Zamponi GW; Turner RW
J Neurosci; 2017 Nov; 37(46):11255-11270. PubMed ID: 29038242
[TBL] [Abstract][Full Text] [Related]
27. The intermediate-conductance calcium-activated potassium channel KCa3.1 contributes to atherogenesis in mice and humans.
Toyama K; Wulff H; Chandy KG; Azam P; Raman G; Saito T; Fujiwara Y; Mattson DL; Das S; Melvin JE; Pratt PF; Hatoum OA; Gutterman DD; Harder DR; Miura H
J Clin Invest; 2008 Sep; 118(9):3025-37. PubMed ID: 18688283
[TBL] [Abstract][Full Text] [Related]
28. Blood-brain barrier KCa3.1 channels: evidence for a role in brain Na uptake and edema in ischemic stroke.
Chen YJ; Wallace BK; Yuen N; Jenkins DP; Wulff H; O'Donnell ME
Stroke; 2015 Jan; 46(1):237-44. PubMed ID: 25477223
[TBL] [Abstract][Full Text] [Related]
29. The role and mechanism of K
Ma XZ; Pang ZD; Wang JH; Song Z; Zhao LM; Du XJ; Deng XL
Exp Cell Res; 2018 Aug; 369(2):208-217. PubMed ID: 29792849
[TBL] [Abstract][Full Text] [Related]
30. Effects of Intermediate-Conductance Ca(2+)-Activated K(+) Channels on Human Endometrial Carcinoma Cells.
Zhang Y; Feng Y; Chen L; Zhu J
Cell Biochem Biophys; 2015 Jun; 72(2):515-25. PubMed ID: 25608633
[TBL] [Abstract][Full Text] [Related]
31. Inhibitory effects of candesartan on KCa3.1 potassium channel expression and cell culture and proliferation in peripheral blood CD4
Li H; Zhao JL; Zhang YM; Han SX
Clin Exp Hypertens; 2018; 40(4):303-311. PubMed ID: 29388859
[TBL] [Abstract][Full Text] [Related]
32. Histidine phosphorylation relieves copper inhibition in the mammalian potassium channel KCa3.1.
Srivastava S; Panda S; Li Z; Fuhs SR; Hunter T; Thiele DJ; Hubbard SR; Skolnik EY
Elife; 2016 Aug; 5():. PubMed ID: 27542194
[TBL] [Abstract][Full Text] [Related]
33. Neuronal expression of the intermediate conductance calcium-activated potassium channel KCa3.1 in the mammalian central nervous system.
Turner RW; Kruskic M; Teves M; Scheidl-Yee T; Hameed S; Zamponi GW
Pflugers Arch; 2015 Feb; 467(2):311-28. PubMed ID: 24797146
[TBL] [Abstract][Full Text] [Related]
34. KCa3.1 constitutes a pharmacological target for astrogliosis associated with Alzheimer's disease.
Yi M; Yu P; Lu Q; Geller HM; Yu Z; Chen H
Mol Cell Neurosci; 2016 Oct; 76():21-32. PubMed ID: 27567685
[TBL] [Abstract][Full Text] [Related]
35. Upregulation of KCa3.1 K(+) channel in mesenteric lymph node CD4(+) T lymphocytes from a mouse model of dextran sodium sulfate-induced inflammatory bowel disease.
Ohya S; Fukuyo Y; Kito H; Shibaoka R; Matsui M; Niguma H; Maeda Y; Yamamura H; Fujii M; Kimura K; Imaizumi Y
Am J Physiol Gastrointest Liver Physiol; 2014 May; 306(10):G873-85. PubMed ID: 24674776
[TBL] [Abstract][Full Text] [Related]
36. Phosphatidylinositol 3-phosphate indirectly activates KCa3.1 via 14 amino acids in the carboxy terminus of KCa3.1.
Srivastava S; Choudhury P; Li Z; Liu G; Nadkarni V; Ko K; Coetzee WA; Skolnik EY
Mol Biol Cell; 2006 Jan; 17(1):146-54. PubMed ID: 16251351
[TBL] [Abstract][Full Text] [Related]
37. Ca
Ohya S; Kito H
Biol Pharm Bull; 2018; 41(8):1158-1163. PubMed ID: 30068864
[TBL] [Abstract][Full Text] [Related]
38. The combined activation of K
Pillozzi S; D'Amico M; Bartoli G; Gasparoli L; Petroni G; Crociani O; Marzo T; Guerriero A; Messori L; Severi M; Udisti R; Wulff H; Chandy KG; Becchetti A; Arcangeli A
Br J Cancer; 2018 Jan; 118(2):200-212. PubMed ID: 29161243
[TBL] [Abstract][Full Text] [Related]
39. Critical regulation of atherosclerosis by the KCa3.1 channel and the retargeting of this therapeutic target in in-stent neoatherosclerosis.
Zhu YR; Jiang XX; Zhang DM
J Mol Med (Berl); 2019 Sep; 97(9):1219-1229. PubMed ID: 31254004
[TBL] [Abstract][Full Text] [Related]
40. Up-regulation of KCa3.1 promotes human airway smooth muscle cell phenotypic modulation.
Yu ZH; Wang YX; Song Y; Lu HZ; Hou LN; Cui YY; Chen HZ
Pharmacol Res; 2013 Nov; 77():30-8. PubMed ID: 24055799
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
